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ABSTRACT
Diabetes is one of the most common comor-
bidities in hospitalized patients with coron-
avirus disease 2019 (COVID-19). Inpatient
hyperglycemia during this pandemic has been
associated with worse outcomes, so it is
mandatory to implement effective glycemic
control treatment approaches for inpatients
with COVID-19. The shortage of personal pro-
tective equipment, the need to prevent staff
exposure, or the fact that many of the health-
care professionals might be relatively unfamiliar
with the management of hyperglycemia may
lead to worse glycemic control and, conse-
quently, a worse prognosis. In order to reduce
these barriers, we intend to adapt established
recommendations to manage hyperglycemia
during this pandemic in critical and noncritical
care settings.
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Diabetes is one of the most common
comorbidities in hospitalized patients
with coronavirus disease 2019 (COVID-
19).
Inpatient hyperglycemia during the
COVID-19 pandemic has been associated
with worse outcomes, but improvement
of glycemic control can reduce
complications associated with
hyperglycemia.
Effective glycemic control treatment
approaches for inpatients with COVID-19
are needed while, at the same time,
limiting the exposure of healthcare
professionals. An individualized approach
adapting the established
recommendations for the management of
hyperglycemia in hospitalized patients
may reduce the barriers during COVID-19
pandemic.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13182836.
INTRODUCTION
Diabetes is one of the most common comor-
bidities of coronavirus disease 2019 (COVID-
19), caused by severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) infection.
The prevalence of diabetes among people
affected by COVID-19 is not higher than that
observed in the general population, suggesting
that diabetes does not increase the risk of SARS-
CoV-2 infection, but can worsen the outcome of
the disease [1, 2]. In fact, clinical studies have
found diabetes to be a major risk factor for dis-
ease severity and mortality [3, 4]. Patients with
diabetes and/or uncontrolled hyperglycemia are
more than twice as likely to be admitted to
intensive care units (ICU) and mortality is up to
three times higher compared to patients with-
out diabetes and/or uncontrolled hyper-
glycemia [5].
It is well established that inpatient hyper-
glycemia, with or without known diabetes,
contributes to a significant increase in morbid-
ity, mortality, length of hospital stay, and
healthcare costs, and that better glycemic con-
trol improves clinical outcomes [6–8]. This was
also evident in prior coronavirus infection out-
breaks like the severe acute respiratory syn-
drome (SARS) [9].
Several mechanisms have linked hyper-
glycemia to the worse prognosis of COVID-19.
These mechanisms include those related to
hyperglycemia and glycemic control as well as
the impaired immune and inflammatory
response caused by hyperglycemia [10]. Poor
glycemic control has been associated with worse
outcomes, including higher resource utiliza-
tion, prolonged length of hospitalization, mul-
ti-organ injuries, and higher mortality [10–13].
Hyperglycemia in patients with and without
diabetes can also have a negative impact on the
efficacy of COVID-19 therapies, such as tocili-
zumab [14]. Frequent comorbidities associated
with diabetes, such as obesity and hypertension,
have also been associated with poor prognosis
[15]. However, a recent study has shown that
diabetes is associated with poor early outcomes
among hospitalized patients with COVID-19,
after adjustment for obesity [16]. In addition,
accelerated respiratory deterioration has
recently been identified as another mechanism
whereby hyperglycemia can lead to worse out-
comes of COVID-19 [17].
While some of these mechanisms remain to
be elucidated, it seems clear that optimizing
glycemic control can be crucial to improve
COVID-19 outcomes. Well-controlled blood
glucose (BG) levels, defined as BG between 70
and 180 mg/dL (3.9 and 10.0 mmol/L) have
been associated with reduced medical inter-
ventions, major organ injuries, and all-cause
mortality [11]. In fact, for every 10 mg/dL
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(0.6 mmol/L) drop in glucose levels between
admission and 18 days, an 11% relative decrease
in severe disease risk has been described in
patients with hyperglycemia [10].
The limited data available suggest that gly-
cemic control in patients with COVID-19 is
inadequate. An observational study that evalu-
ated glycemic control among hospitalized
patients with COVID-19, diabetes, and acute
hyperglycemia described 39.1% of BG values
above 180 mg/dL (10.0 mmol/L) and 37.8% of
the time of admission spent with a mean BG
above 180 mg/dL (10.0 mmol/L) [12]. Another
study showed 56.6% of capillary BG tests above
the recommended target of 140–180 mg/dL
(7.8–10.0 mmol/L) [18]. This may be due to
high levels of stress, inflammation, a cytokine-
mediated insulin-resistant state and lack of
adequate protocols for glucose management
[19]. It is also possible that the SARS coronavirus
can penetrate into pancreatic islets and damage
beta cells leading to insulin deficiency, thereby
aggravating the course of diabetes and trigger-
ing acute hyperglycemia even in people without
diabetes [20, 21]. This is supported by the
observation of frequent cases of ketosis and
severe diabetic ketoacidosis (DKA) at the time of
hospital admission [22]. On the other hand, a
rather large number or hypoglycemic episodes
at hospital admission have also been reported,
probably favored by COVID-19-induced anor-
exia without concomitant adaptation of glu-
cose-lowering drugs [18, 20]. There are other
factors associated with BG fluctuation that are
especially relevant in patients with diabetes and
COVID-19, such as the use of glucocorticoids,
that can lead to large glycemic excursions
which should be considered in setting the
insulin pattern [23].
In addition, healthcare workers can face
challenges that need careful attention. Special-
ists from all disciplines may have to manage
patients with COVID-19 outside of their usual
specialty areas and, therefore, clinicians rela-
tively unfamiliar with managing hyperglycemia
may be required to do so [24]. The shortage of
personal protective equipment and the need to
prevent healthcare workers’ exposure can also
hinder glycemic control in patients with
COVID-19.
In this clinical scenario, there is an urgent
need to implement effective glycemic control
treatment approaches for inpatients with
COVID-19 [25]. However, no data is available
regarding the most appropriate management of
hyperglycemia in patients infected by SARS-
CoV-2. Until then, given the aforementioned
challenges, we intend to adapt established rec-
ommendations to manage hyperglycemia dur-
ing this pandemic in critical and noncritical
care settings. In Table 1 we summarize the main
recommendations for the management of
hyperglycemia in critically ill and noncritically
ill patients with COVID-19 according to their
clinical situation. This article is based on pre-
viously conducted studies and does not contain
any studies with human participants or animals
performed by any of the authors.
MANAGEMENT
OF HYPERGLYCEMIA IN CRITICAL
PATIENTS WITH COVID-19
Glycemic Targets
Glycemic control goals in the ICU have been
the subject of debate during the past 2 decades.
It is generally accepted that intensive glycemic
control [80–110 mg/dL (4.4–6.1 mmol/L)] com-
pared to moderate control [140–180 mg/dL
(7.8–10.0 mmol/L)] does not provide any bene-
fit and in fact can increase the risk of hypo-
glycemia and even mortality [26, 27]. There is
agreement that glucose levels above 180 mg/dL
(10.0 mmol/L) may increase the risk of hospital
complications. However, the lower limit for
glycemia target is less well established and val-
ues greater than 110 mg/dL (6.1 mmol/L) are
generally recommended in order to minimize
the risks of hypoglycemia [7]. The GLUCO-
CABG study showed a significant reduction in
complications among patients undergoing
coronary artery bypass graft surgery without
diabetes comparing a glucose target of
100–140 mg/dL (5.6–7.8 mmol/L) to a target of
141–180 mg/dL (7.8–10.0 mmol/L) [28], and the
results of Krinsley et al.’s study in critically ill
patients support a BG target of 80–140 mg/dL
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(4.4–7.8 mmol/L) for patients without diabetes
and with diabetes when HbA1c is less than 7%
(53 mmol/mol), but 110–160 mg/dL (6.1–
8.9 mmol/L) in those with HbA1c levels of at
least 7% (53 mmol/mol) [29]. Also deserving
attention is the fact that glycemic variability per
se has been associated with higher mortality
rates than hyperglycemia in septic patients [30].
It has therefore been suggested that glycemic
variability has to be part of the management of
hyperglycemia, even in ICU patients [31]. These
data, like those established for outpatient dia-
betes management, support a potential benefit
of a personalized glycemic target in critically ill
patients.
Clinical guidelines recommend maintaining
glucose levels between 140 and 180 mg/dL
(7.8–10.0 mmol/L) for most critically ill patients
[32] and more stringent goals of 110–140 mg/dl
(6.1–7.8 mmol/L) may be reasonable for selec-
ted patients, as long as they can be achieved
without significant hypoglycemia [7, 28, 29]. In
Table 1 Hyperglycemia management in critically and noncritically ill patients with COVID-19































Not oral intake Basal-correction Every 4–6 h##
Oral intake Basal-bolus-
correction




















Before meals and at
bedtime##
BG blood glucose, T1D type 1 diabetes, T2D type 2 diabetes, DM diabetes mellitus
*110–140 mg/dL (6.1–7.8 mmol/L) may be reasonable for selected patients, as long as it can be achieved without significant
hypoglycemia
**110–140 mg/dL (6.1–7.8 mmol/L) may be reasonable for stable patients with mild disease and previous tight glycemic
control. BG levels[ 180 mg/dL (7.8 mmol/L) might be acceptable for patients who are at high risk of hypoglycemia or
who have limited life expectancy
# To calculate insulin requirements during the first 24 h. Then intensify to a basal-correction or basal-bolus regimen
## Consider the use of continuous glucose monitoring if feasible to limit fingersticks
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accordance with Pasquel et al. [33], we consider
that these recommendations could be extended
to critical patients with COVID-19.
Insulin Therapy
Insulin should be the treatment of choice for
critically ill patients with COVID-19. The main
aims of a safe and effective insulin regimen
should be to reduce contact frequency, reduce
glucose variability, minimize risk of severe
hypoglycemia, and improve overall glycemic
control [34]. As a result of the stress caused by
SARS-CoV-2 infection and other factors, such as
continuous tube feeding in patients on artificial
ventilation and the risk of hypoglycemia when
tube feeding is interrupted, or the use of high
doses of corticosteroids, patients may suffer
from great glycemic excursions [34]. To achieve
glycemic targets, continuous intravenous insu-
lin infusion, based on validated written or
computerized protocols, is the most effective
method [7, 35, 36]. The protocols that do not
need a calculation of insulin doses (printed with
decision columns and computerized protocols)
are preferable to those that require calculations
to decide the dose. Training of physicians and
especially nurses in the efficient use of the
protocol as well as predefining adjustments
before important changes in BG and/or situa-
tions in which corticosteroids, vasopressors,
parenteral nutrition, etc., are removed or added
is important for protocol safety. However, the
main factor that contributes to the safety of the
protocol is the frequency of glycemic monitor-
ing. The majority of insulin infusion protocols
demand a minimum of hourly glucose moni-
toring for successful glycemic target achieve-
ment while reducing the risk of hypoglycemia.
Checking glucose levels with a meter and test
strips requires caregivers to enter a patient’s
room. In order to minimize healthcare workers’
exposure when managing hyperglycemia in
critically ill patients with COVID-19, for
hemodynamically stable patients who are not
on parenteral nutrition or high-dose corticos-
teroids, we recommend that the use of subcu-
taneous basal-bolus-correction or basal-
correction insulin regimens should be
considered instead of intravenous insulin infu-
sion and check BG levels four times a day
together with other nursing activities to reduce
the need to enter a patient’s room. Transfer
from intravenous to subcutaneous insulin
administration will be recommended when the
patient is clinically stable [37, 38]. The initial
dose of subcutaneous insulin administration at
the time of transition can be determined as
60–80% of the insulin administered intra-
venously during the preceding 24 h. To avoid
rebound hyperglycemia after transition, a suffi-
cient duration of overlap with the insulin
infusion and the subcutaneous insulin admin-
istration is required. Short-acting insulin can be
administered 1 to 2 h and long-acting insulin 2







The American Diabetes Association (ADA) pro-
poses the range of 140–180 mg/dL (7.8–
10.0 mmol/L) as a target level of BG for the
majority of noncritically ill patients [39]. How-
ever, the ideal glucose goals for noncritically ill
patients remain undefined, and current recom-
mendations are based mostly on retrospective
studies, clinical experience, and judgment [7].
Evidence regarding appropriate glycemic
targets for hospitalized patients with COVID-19
is lacking. As mentioned before, BG levels
maintained between 70 and 180 mg/dL (3.9 and
10.0 mmol/L) have been associated with better
clinical outcomes [11]. Premeal and fasting BG
values below 140 mg/dL (7.8 mmol/L) with
maximal random BG below 180 mg/dL
(10.0 mmol/L) might be appropriate in
stable patients with mild disease and previous
tight glycemic control, while glucose levels
above 180 mg/dL (10.0 mmol/L) might be
acceptable in patients who are at high risk of
hypoglycemia or who have limited life
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expectancy, as a way of minimizing the risk of
hypoglycemia [7].
Insulin Therapy
There are limited data available about the effi-
cacy and safety of non-insulin agents in hospi-
talized patients, almost restricted to dipeptidyl
peptidase 4 (DPP4) inhibitors [40–44]. These
agents in combination with basal insulin may
represent an alternative in patients with
COVID-19 and mild to moderate hyperglycemia
[33]. DPP4 inhibitors have also been suggested
to have a protective effect on COVID-19 [45].
However, recent studies found no association
between the use of DPP4 inhibitors before
admission and COVID-19 prognosis [20, 46, 47].
Moreover, we still do not have data on their use
in hospitalized patients with COVID-19, and
they may not be available in many hospitals.
The incorporation of non-insulin drugs expands
the therapeutic options and consequently the
complexity of the prescription, which can be
especially difficult when clinicians are unfa-
miliar with managing hyperglycemia. Gluca-
gon-like peptide 1 (GLP-1) receptor agonists
could be an attractive option, but they may
increase the risk of gastrointestinal side effects
[48]. Metformin and sodium-glucose cotrans-
porter 2 (SGTL2) inhibitors should be discon-
tinued at admission, because of the risk of lactic
acidosis and DKA, respectively [49]. Some
authors hypothesized that SGLT2 inhibitors
could be effective in patients with hypoxemia
and interstitial lung edema due to SARS-CoV-2
infection [50, 51]. Experience with three hos-
pitalized patients without diabetes has been
reported, showing no beneficial effects with the
use of SGLT2 inhibitors [50]. All other oral
agents, such as sulfonylureas or thiazolidine-
diones, should also be discontinued at
admission.
Insulin is still considered the most appro-
priate pharmacologic agent for effectively con-
trolling glycemia in hospital. Several regimens
have proven to be effective for achieving and
maintaining glycemic control. Current clinical
guidelines recommend basal-bolus insulin regi-
mens as the standard care for hospitalized
patients with hyperglycemia and diabetes in
noncritical care setting [32, 36]. There is no data
regarding the most appropriate regimen for
patients with COVID-19, but the importance of
achieving good glycemic control is evident [10].
A lot of evidence supports the use of basal-
bolus regimens in noncritically ill patients.
Randomized clinical trials have shown that
basal-bolus treatment improves glycemic con-
trol and reduces the rate of hospital complica-
tions compared with reactive, or sliding-scale,
insulin regimens [8, 52]. Compared to premixed
insulin (70/30 NPH/regular insulin), a basal-
bolus regimen has shown comparable glycemic
control, but significantly fewer hypoglycemic
episodes in medical and surgical patients [53]. A
basal plus regimen compared with a standard
basal-bolus regimen in medical and surgical
patients with type 2 diabetes treated with diet,
oral antidiabetic agents, or low-dose insulin
resulted in a similar improvement in glycemic
control without differences in hypoglycemia
[54]. As for the types of insulin, regimens using
insulin analogues and human insulin result in
similar glycemic control in the hospital setting
[55]. However, NPH insulin-based basal-bolus
regimens have been largely supplanted by
insulins analogue because of a perceived lower
risk of hypoglycemia and because NPH insulin
usually cannot be administered once daily.
There are limited data regarding the use of new
basal insulin analogues in the hospital setting. A
recent study comparing glargine U300 and
glargine U100 in a basal-bolus regimen in gen-
eral medical and surgical patients with type 2
diabetes resulted in similar glycemic control,
but significantly lower rates of clinically signif-
icant hypoglycemia [BG below 54 mg/dL
(3 mmol/L)] with the use of glargine U300 [56].
In line with this study, another recent study in
people with type 2 diabetes insufficiently con-
trolled with basal insulin and/or non-insulin
antidiabetic drugs, the COBALTA trial, confirms
the efficacy and safety of insulin glargine U300
during hospitalization. This study also demon-
strates that therapy intensification at discharge
with glargine U300 is an effective strategy,
improving HbA1c by 1.6% at months 3 and 6
post discharge with an adequate safety profile
and a high degree of treatment satisfaction [57].
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On the basis of these results, an insulin reg-
imen with basal, prandial, and correction com-
ponents would be the preferred treatment for
noncritically ill hospitalized patients with
COVID-19 and good nutritional intake, and
basal insulin or a basal plus correction for
patients with poor oral intake or those in which
oral intake cannot be ensured [32]. Prolonged
use of sliding-scale insulin regimens as the sole
treatment of hyperglycemia is strongly dis-
couraged [32].
Insulin Therapy in Glucocorticoid-
Induced Hyperglycemia
The use of glucocorticoid therapy can aggravate
or precipitate hyperglycemia in hospitalized
patients with COVID-19 with and without
known diabetes [58]. Regarding the use of high
doses of corticosteroids in these patients, some
authors have described their experience adding
NPH insulin in a dose of 20–30 units in the
morning in addition to the current insulin
regimen as an efficient strategy to minimize the
impact of steroids on BG values [34]. In our
experience, the best option is to add the calcu-
lated increase in insulin dose, considering body
weight and glucocorticoid dose, to the patient’s
usual total dose, distributing it according to the
usual insulin regimen and glucocorticoid
schedule [23].
GLUCOSE MONITORING
IN HOSPITAL IN PATIENTS
WITH COVID-19
Maintaining an adequate glycemic control
usually requires multiple daily glucose mea-
surements, which can be a challenge in patients
under strict isolation. The implementation of
technology that minimizes staff exposure while
maintaining standard of care for hospitalized
patients with diabetes is essential [59].
The US Food and Drug Administration (FDA)
recognizes that home-use BG meters may be
used by patients with diabetes who are hospi-
talized because of COVID-19 to check their own
BG levels and provide the readings to the
healthcare workers caring for them [60]. Nev-
ertheless, a way to monitor BG remotely, from
outside the isolated rooms, is required [59]. This
could be achieved by using BG meters that
transmit the data via Bluetooth to an app or to a
cloud. However, the use of continuous glucose
monitoring (CGM) might be the ideal way to
monitor BG in patients with COVID-19. It
would allow, on the one hand, remote moni-
toring; on the other hand, it would help to
enable BG control with low variability in the
intended target range [31].
Inpatient clinical trials have tested the
accuracy, safety, and efficacy of CGM technol-
ogy in hospital, in both critical and noncritical
patients [61–63]. Some experiences have already
been reported in noncritical patients with
COVID-19 with type 1 and type 2 diabetes, with
the use of Guardian Connect (Medtronic), with
significant improvement in mean glucose levels
in all patients [59]. The main challenges for the
use of CGM in hospital include training
healthcare workers, the need for calibration
procedures with some CGM systems, and cost.
There are some systems such as FreeStyle Libre
or Dexcom G6 that do not require BG calibra-
tion, minimizing risk of staff exposure and
burden. Recently, the FDA approved the use of
both FreeStyle Libre and Dexcom for inpatient
use during the COVID-19 healthcare crisis in
noncritically ill patients, but not in the criti-
cally ill [64–66]. Both systems can securely
transmit glucose measurement data to digitally
connected devices. As far as we know, no
experiences have been reported with the use of
these two CGM systems in hospitalized patients
with COVID-19.
Some issues should be taken into account
with the use of CGM systems in patients with
COVID-19. Hypoxemia and possible reduction
in peripheral perfusion could interfere with the
accuracy of interstitial glucose measurement,
especially in critically ill patients [67]. Acet-
aminophen, a commonly used antipyretic in
patients with COVID-19, can interfere with
CGM readings in some systems and may cause a
CGM to overestimate glucose [68] (not in Free-
Style Libre or Dexcom G6). Glucose values in
patients wearing a device that may be impacted
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by acetaminophen should be interpreted with
caution.
Regarding ICU patients, the integration of
computer-guided insulin infusion with CGM or
further development of new automated insulin
delivery systems may be ideal [33]. Data about
the use of hybrid closed-loop insulin infusion
systems in critically ill patients are scarce.
However, two recent cases of type 1 diabetes in
patients with COVID-19 using t:slim Control IQ
hybrid closed-loop system have been described,
with optimal glycemic levels and minimal
variability [34]. However, we will have to wait
for more data on its efficacy and safety in criti-
cally ill patients before we can recommend its
use.
Both the use of CGM systems and the use of
hybrid closed-loop insulin infusion systems
would require specific protocols for guidance, as
well as access to specialist care [69]. Having an
endocrinologist on consult, even over the
phone or virtually, could help with all the
approaches proposed [19, 70].
CONCLUSIONS
Improvement of glycemic control can reduce
complications associated with hyperglycemia in
hospitalized patients infected by SARS-CoV-2.
Effective glycemic control treatment approa-
ches for inpatients with COVID-19 are needed
while, at the same time, limiting the exposure
of healthcare professionals. Although we do not
yet have data regarding the optimal glycemic
targets for inpatients with COVID-19, it is clear
that extremes of BG can lead to poor outcomes,
and that insulin is the most appropriate treat-
ment for effectively controlling glycemia in
hospital. A target glucose range of 110–180 mg/
dL (6.1–10.0 mmol/L) may be appropriate for
most critically and noncritically ill patients,
individualized according to patient characteris-
tics and clinical situation. A continuous intra-
venous insulin infusion and scheduled basal-
bolus correction insulin are the preferred regi-
mens for glycemic control in critically and
noncritically ill hospitalized patients, respec-
tively. An individualized approach adapting the
established recommendations may reduce the
aforementioned barriers during the COVID-19
pandemic. The use of subcutaneous insulin
regimens in clinically stable patients may facil-
itate the reduction of the number of BG con-
trols and, therefore, the exposure of the staff. In
the same way, the implementation of technol-
ogy that allows BG remote monitoring could
help to limit fingersticks to check BG and,
consequently, minimize staff exposure. The
FDA approved the use of both FreeStyle Libre
and Dexcom for inpatient use during the
COVID-19 healthcare crisis. Further research
regarding the evaluation of these changes in
care is warranted in order to adapt our
protocols.
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44. Pérez-Belmonte LM, Osuna-Sánchez J, Millán-
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